Clinical trial
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the…
NCT00106431 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00106431 |
|---|---|
| Title | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) |
| Official title | A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-cell Lymphoma |
| Lead sponsor | Celgene, Industry |
| Collaborators | Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cutaneous T-cell Lymphoma |
| Intervention type | Drug |
| Interventions | romidepsin (depsipeptide, FK228) |
| Enrollment | 102 |
| Start date | Jan 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Mar 25, 2005 |
| Last update posted | Oct 30, 2019 |
| Countries | France, Germany, Poland, Russia, United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: